NASDAQ$TNGX
Tango Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Tango Therapeutics Inc Q1 fiscal 2026: $0.00 revenue, $45.5M net loss
for the year ended December 31, 2025 and this Quarterly Report on Form 10-Q. (SEC accession 0001193125-26-221656)
- Revenue: $0.00
- Net loss: $45.5M
- Diluted EPS: $-0.32
- Operating income: $-48.8M
Headline financials
Revenue & EPS history
Tango Therapeutics · Revenue · Quarterly
$0
Q1 2026-100%vs Q1 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
+0.6%
Avg return
Earnings day
+6.7%
Avg return
5 days after
+25.5%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+36.4%
Q4 2025
Best reaction
-45.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.6% | -12.1% | — | |
| Q4 2025 | +36.4% | +33.6% | +75.1% | |
| Q3 2025 | +0.2% | -1.7% | +23.6% | |
| Q1 2025 | +17.1% | +31.6% | +315.8% | |
| Q4 2024 | -6.5% | -21.0% | -36.9% | |
| Q3 2024 | -45.4% | -34.7% | -34.7% | |
| Q2 2024 | -1.8% | -5.7% | +20.9% | |
| Q1 2024 | -0.8% | -6.9% | -12.1% | |
| Q4 2023 | -9.7% | -14.4% | -17.4% | |
| Q3 2023 | +3.8% | -12.1% | +6.6% | |
| Q2 2023 | +1.2% | +120.9% | +113.5% | |
| Q1 2023 | +6.4% | +4.4% | -0.3% | |
| Q4 2022 | -9.4% | -5.3% | -21.6% | |
| Q3 2022 | -5.3% | +6.7% | -1.3% | |
| Q2 2022 | +22.4% | +32.8% | -8.1% | |
| Q1 2022 | -7.6% | +1.2% | -3.8% | |
| Q4 2021 | +0.3% | +6.8% | +1.3% | |
| Q3 2021 | +0.4% | +5.2% | -10.7% | |
| Q2 2021 | +1.1% | -2.2% | +49.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro